Autolus Therapeutics (NASDAQ:AUTL) Reaches New 52-Week Low – Should You Sell?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low during trading on Thursday . The stock traded as low as $2.29 and last traded at $2.29, with a volume of 2277337 shares changing hands. The stock had previously closed at $2.49.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AUTL. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, December 5th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Down 8.0 %

The firm has a 50-day moving average price of $3.52 and a 200 day moving average price of $3.82. The firm has a market capitalization of $609.36 million, a PE ratio of -1.89 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the business earned ($0.26) earnings per share. Equities research analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AUTL. Wellington Management Group LLP lifted its holdings in Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC raised its stake in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Armistice Capital LLC boosted its holdings in Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares during the period. Affinity Asset Advisors LLC grew its stake in Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after purchasing an additional 925,000 shares in the last quarter. Finally, Great Point Partners LLC increased its holdings in Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.